Medicinal Chemistry News and Research

RSS

Diakron licenses anticoagulant drug candidate from Merck

Diakron Pharmaceuticals, Inc. announced today the signing of an exclusive license agreement for a novel investigational oral anticoagulant drug candidate discovered and developed through Phase I clinical trials by Merck & Co. Inc. Under the terms of the agreement, Diakron has the exclusive rights to develop, and, if approved, market and distribute the compound worldwide.

13 Aug 2008

Researchers find a cancer-inhibiting cyanobacteria that grows on coral reefs

University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease.

10 Aug 2008

Discovery of new drug candidates to combat bird flu

As the specter of a worldwide outbreak of avian or "bird flu" lingers, health officials recognize that new drugs are desperately needed since some strains of the virus already have developed resistance to the current roster of anti-flu remedies.

2 Jul 2008

Discovery of mechanism of action of antibiotic able to reduce neuronal cell death in brain

Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer's disease, Huntington's disease, epilepsy, stroke, dementia and malignant gliomas.

11 May 2008

Biopharmaceutical spin-out company Domainex, secures funding

Headquartered in London, Domainex is a contract research company specialising in the provision of structural biology and chemistry services to major pharmaceutical and biotechnology firms. The Company is also developing a pipeline of pre-clinical drugs and targets.

From Domainex 23 Apr 2008

Scientists identify potential therapy targets for schistosomiasis

A research team supported by the National Institutes of Health (NIH) Roadmap and the National Institute of Allergy and Infectious Diseases (NIAID) has identified chemical compounds that hold promise as potential therapies for schistosomiasis, a parasitic disease that afflicts more than 200 million people worldwide.

18 Mar 2008

Discovery of chemical compounds that hold promise as potential therapies for schistosomiasis

17 Mar 2008

Experimental cancer drug MI-219 promising in preclinical studies

Researchers have long searched for a novel cancer drug that activates a certain protein to kill tumor cells.

4 Mar 2008

New fast-acting antidote to cyanide poisoning

University of Minnesota Center for Drug Design and Minneapolis VA Medical Center researchers have discovered a new fast-acting antidote to cyanide poisoning.

28 Dec 2007

University of Illinois at Chicago receives $2.2 million grant to develop drugs to suppress cocaine cravings

The University of Illinois at Chicago College of Pharmacy has received a $2.2 million federal grant to develop therapeutics to suppress the cravings of cocaine addicts.

19 Nov 2007

New understanding of vagus nerve's role in regulating inflammation

It used to be dogma that the brain was shut away from the actions of the immune system, shielded from the outside forces of nature.

24 Oct 2007

New drugs to combat bioterrorism

The University of Illinois at Chicago College of Pharmacy has received a grant from the U.S. Department of Defense to develop new drugs to combat agents of bioterrorism.

7 Aug 2007

Portmanteau inhibitors offer new way to tackle HIV

Researchers at the University of Minnesota's Center for Drug Design have developed a new method to combat HIV/AIDS, potentially replacing the traditional cocktail drug approach.

24 Jul 2007

Experimental Alzheimer's drug begins clinical trials

A drug based on the design of a Purdue University researcher to treat Alzheimer's disease began the first phase of human clinical trials this week.

23 Jun 2007

New area of stroke drug discovery for the 22nd century

A new therapy to re-activate silenced genes in patients who suffer from neurodegenerative diseases or stroke is being developed by researchers at the University of Illinois at Chicago and Cornell University.

17 Jun 2007

University of Leicester launches one-year Masters degree in Cancer Chemistry

The degree is the first of its kind in the country, fulfilling a need to provide graduates with skills in the chemistry and biology of cancer, and direct experience of some of the very latest research in the field.

22 May 2007

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb Company and Isis Pharmaceuticals have announced a collaboration to discover, develop and commercialize novel antisense drugs targeting proprotein convertase subtilisin kexin 9 (PCSK9) for the prevention and treatment of cardiovascular disease.

10 May 2007